On 15 June, the European Medicines Agency began a rolling review of an adapted version of Pfizer Inc./BioNTech SE’s mRNA COVID-19 vaccine, Comirnaty, which is designed to provide better protection against a specific variant or variants of the SARS-CoV-2 virus.
“The details about the adapted vaccine, for example whether it will specifically target one or more SARS-CoV-2 variants or subvariants, are not yet defined,” the EMA said, although it noted that its review would initially focus on the CMC (chemistry,